Theralase Technologies Inc.
OTC Bulletin Board : TLTFF

Theralase Technologies Inc.

April 30, 2007 09:01 ET

Theralase Technologies Inc. Announces Financial Results for Fiscal 2006

TORONTO, ONTARIO--(CCNMatthews - April 30, 2007) - Theralase Technologies Inc. (TSX VENTURE:TLT) (OTCBB:TLTFF) announced audited financial results for the year ended December 31, 2006.

Revenues totaled $1,437,256 for the twelve month period ended December 31st, 2006, a 20% increase over the $1,206,909 in revenues reported for the same period last year. Total revenue for 2006 was potentially $1,646,750 or a 36% increase in revenues for the same period last year; however, sales returns of $209,494 resulted in a total reported revenue of $1,437,256. These sales returns were due to the discontinuation of a US manufacturing representative agreement, whereby product previously sold to a US manufacturing representative under the terms of the agreement, was recalled in the 4th quarter and resold as demonstration models. As a testament to the strength of the product brand and the team behind it, 95% of the recalled product was repatriated, recertified and resold in less than three months at slightly discounted prices.

Cost of sales for the current period under review was $368,617, resulting in a gross profit, before expenses, of $1,068,639 for an operating margin of 74%, compared with a 75% margin for the same period last year.

Expenses increased by 32% for the current year under review to $850,886 from $644,677, as the Company increased the depth of personnel in the production and finance departments and accelerated our marketing efforts in the US market.

The Company reported a loss of $281,997 for the twelve month period ended December 31st, 2006, but after accounting for non cash expenses such as amortization and stock based compensation, the Company would have reported earnings of $61,254.

Significant achievements during the year are as follows:

Biofeedback Project

Theralase's patented TLC-2000 biofeedback technology sets a new standard in the therapeutic laser marketplace by introducing technology that is able to precisely target tissue to within a millimeter with an exact dosage of energy; hence, dramatically improving the efficacy of patient based treatments. The TLC-2000 is also a learning device that remembers successful laser dosages and transmits these to all users through a HIPAA compliant central databank. The research side of the project has been successfully completed in 2006 and Theralase is currently commercializing the TLC-2000 biofeedback technology for introduction to the international medical market in the 2nd quarter 2008.
Photo Dynamic Compound (PDC) Therapy Project

Three of Theralase's patented photodynamic compounds (PDC) have been synthesized, analyzed and stored. Theralase plans to commence a two year project aimed at harnessing the energy of these PDC's with the power of the patented Theralase laser technology in the applications of cancer, bacterium and potentially fat cells. In-vitro and in-vivo analysis of the PDC's is slated to commence the 2nd quarter 2007 with initial results available in the 1st quarter 2008. Commencement of the Theralase TLC-3000 laser system to activate the compounds is planned to commence 2nd quarter 2008.

Smoking Cessation / Weight Loss

Theralase introduced a new auriculotherapy (ear acupuncture) probe for smoking cessation and weight loss. The Theralase auriculotherapy system has been granted a Federal Drug and Administration (FDA) Phase 2 Investigational Review Board (IRB) approval for the indications of smoking cessation and weight loss. Theralase continues to expand our knowledge of this field through the establishment of principal investigator locations throughout Canada and the United States.

For detailed financial statements for the year, including Management Discussion and Analysis, please refer to our corporate website at or regulatory website at

Theralase Technologies Inc. designs, develops, manufactures and sells leading edge, proprietary, high powered, super-pulsed therapeutic laser equipment employed in a wide range of biostimulative medical therapy applications. The Theralase technology platform targets several diverse healthcare sectors -- firstly, for non-invasive pain management, control and therapy, including a wide range of neural-musculo-skeletal conditions, arthritic and rheumatologic disorders -- secondly, to bio-stimulate and accelerate wound care and healing, including: bone fracture regeneration and osteoarthritic conditions -- and thirdly, combining proprietary metallic complexes with photo-dynamic lasers to attack specifically-targeted cancerous growths.

For a complete profile of Theralase Technologies Inc. and its products visit

This press release contains forward-looking statements which reflect the Company's current expectations regarding future events. The forward-looking statements involve risks and uncertainties. Actual results could differ materially from those projected herein. The Company disclaims any obligation to update these forward-looking statements.

The TSX Venture Exchange has not reviewed and does not accept responsibility for the adequacy or accuracy of the contents of this release.

Contact Information